Akero Therapeutics — Investor Presentation (June 2023)
64 slides from Akero Therapeutics's investor presentation, Jun 5, 2023
Slide 1: Restoring Balance. Renewing Life. Corporate Presentation June 2023
Exhibit 99.2 Restoring Balance. Renewing Life. Corporate Presentation June 2023
Slide 2: Safe Harbor and Legal Disclaimers
Safe Harbor and Legal Disclaimers This presentation may contain “forward-looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial condit
Slide 3: Corporate Highlights
Corporate Highlights 1 2 3 Potential First-in-Class Building Momentum Toward Experienced & Validated Team & Best-in-Class NASH Drug Phase 3 Pivotal Trials with Substantial Resources • Substantial potential market • Two parallel Phase 2b trials underway • Involved in 20+ FDA approvals opportunity • H
Slide 4: Extensive Development and Commercialization Experience
Extensive Development and Commercialization Experience Involved in 20+ Medicine Approvals Kitty Yale | Chief Development Officer Andrew Cheng, MD, PhD | President & CEO • 19 years at Gilead • Over 25 years at Gilead, Roche, Pfizer • Chief Medical Officer & HIV Division Head • VP, Gilead Worldwide Cl
Slide 5: Providing a Potentially Effective Treatment for NASH
Providing a Potentially Effective Treatment for NASH Reducing liver fat Achieving >10% weight is critical to remove loss is challenging for disease driver patients who are obese Peripheral fat Insulin resistance and is the largest source of Type 2 Diabetes drives liver fat in patients with liver cal
Slide 6: EFX Engineering Potentially Optimal for NASH Efficacy, With Convenient Once-weekly Dosing
EFX Engineering Potentially Optimal for NASH Efficacy, With Convenient Once-weekly Dosing Key attributes Akero proprietary Increases half-life High affinity for Fc-FGF21, from < 2 hours β-Klotho Point mutations to ~3 days Better translation Balanced potency Inactive βKlotho FGFR βKlotho to human at
Slide 7: EFX Acts on Two Major Sources of Liver Fat
EFX Acts on Two Major Sources of Liver Fat With Potential for Optimal Reduction Sources of Fat Flowing into and Acting on both hepatic and peripheral sources of liver Through Liver for Patients with NASH fat is key to optimizing liver fat reduction Dietary Fat Source of Liver Fat FGF Receptor EFX Ac
Slide 8: EFX Direct And Indirect Anti-fibrotic Effects
EFX Direct And Indirect Anti-fibrotic Effects Pathogenesis of Fibrosis Hepatocyte Stress & Death Kupffer Cell Activation Myofibroblast Differentiation Fibrogenesis EFX Anti-Fibrotic Activity Bao, L et al. (2018) Br J Pharmacol 175:3379-3393; Fisher, FM et al. (2014) Gastroenterology 147:1073-1083.e6
Slide 9: Key Regulatory Designations Based on EFX Therapeutic Profile
Key Regulatory Designations Based on EFX Therapeutic Profile Fast Track PRIME Breakthrough Therapy (US FDA - 2021) (EMA - 2020) (US FDA - 2022) • Enables expedited • Enables more frequent • Enables enhanced development regulatory interactions to regulatory support resolve development issues • Signif
Slide 10: Evaluating EFX in Patients with F2-F3 Fibrosis
Evaluating EFX in Patients with F2-F3 Fibrosis STATISTICALLY SIGNIFICANT EFFECTS AFTER 24 WEEKS FIBROSIS IMPROVEMENT FIBROSIS NASH AND IMPROVEMENT RESOLUTION NASH RESOLUTION ©2023 AKERO THERAPEUTICS. 10
Slide 11: HARMONY Trial Design: Pre-Cirrhotic (F2-F3) NASH
HARMONY Trial Design: Pre-Cirrhotic (F2-F3) NASH Key Inclusion Criteria Key Secondary Efficacy Endpoints Phase 2b Primary Endpoint • F2-F3 NASH • ≥ 1-stage fibrosis improvement • NASH Resolution & No • Lipoproteins • MRI-PDFF without worsening of NASH • NAS ≥4 Worsening of Fibrosis • Glycemic Contro
Slide 12: Patient Disposition & Analysis Sets
Week 24 Patient Disposition & Analysis Sets Key Analysis Sets Randomized (N=128) Full Analysis Set – All subjects who were randomized Randomized Not Dosed EFX (N=2) Safety Set – All subjects who received at least one dose of study drug Dosed (N=126) Biomarker Analysis Set – All subjects who have bas
Slide 13: Baseline Demographics
Baseline Demographics Placebo EFX 28mg EFX 50mg Parameter (Mean) (N=43) (N=42) (N=43) Age (Years) 55 57 52 Sex (% Female) 63 69 53 Weight (kg) 108 104 103 Type 2 Diabetes (%) 65 76 70 1 Fibrosis Stage (% F3) 70 64 63 Enhanced Liver Fibrosis (ELF) Score 9.8 9.7 9.8 2 Pro-C3 (μg/L) 16.5 15.3 18.4 3 Li
Slide 14: Consensus Reading of Biopsies: Rigorous Approach to Histopathology
Consensus Reading of Biopsies: Rigorous Approach to Histopathology Based on FDA Input to Minimize Variability Consensus Biopsy Analysis Flow Chart Slides Prepared From Tissue Samples Score 1 Score 2 Key Features of EFX Biopsy Analysis Plan • Biopsies independently scored by two pathologists, with a
Slide 15: Both EFX Doses Achieved Statistical Significance on Primary Endpoint (Fibrosis Improvement)
Both EFX Doses Achieved Statistical Significance on Primary Endpoint (Fibrosis Improvement) Fibrosis Improvement ≥1 Stage 1 & No Worsening of NASH at Week 24 60% 50% * * 41 41% % * * 39 39% % 40% 30% 20% 20% 1 Per FDA guidance, this endpoint is defined as: “Improvement in liver fibrosis greater than
Slide 16: EFX Fibrosis Improvement in Context: Pre-Cirrhotic NASH
EFX Fibrosis Improvement in Context: Pre-Cirrhotic NASH (≥1 Stage Improvement in Fibrosis and No Worsening of NASH) Akero Madrigal Inventiva Madrigal Novo Nordisk Efruxifermin Pegozafermin Lanifibranor Resmetirom Obeticholic Acid Semaglutide Phase 2b (F2-F3) Phase 1b/2a (F2-F3) Phase 2b (F1-F3) Phas
Slide 17: Both EFX Doses Achieved Statistical Significance on Key Secondary Endpoint (NASH Resolution)
Both EFX Doses Achieved Statistical Significance on Key Secondary Endpoint (NASH Resolution) NASH Resolution 1 & No Worsening of Fibrosis at Week 24 100% *** *** 80% 76 76% % 60% ** ** 47% 47% 40% 1 Per FDA guidance, this endpoint is defined as: “Resolution of steatohepatitis on overall histopatholo
Slide 18: EFX NASH Resolution in Context: Pre-Cirrhotic NASH
EFX NASH Resolution in Context: Pre-Cirrhotic NASH (NASH Resolution and No Worsening of Fibrosis) Akero Novo Nordisk Madrigal Inventiva Madrigal Efruxifermin Semaglutide Pegozafermin Lanifibranor Resmetirom Obeticholic Acid Phase 2b (F2-F3) Phase 2b (F2-F3) Phase 1b/2a (F2-F3) Phase 2b (F1-F3) Phase
Slide 19: Both EFX Doses Achieved Statistical Significance on Composite Endpoint
Both EFX Doses Achieved Statistical Significance on Composite Endpoint (Fibrosis Improvement and NASH Resolution) Fibrosis Improvement 1 AND NASH Resolution at Week 24 Patients Achieving Fibrosis Improvement ≥2 Stages 60% and No Worsening of NASH at Week 24 Placebo EFX 28mg EFX 50mg 50% (N=41) (N=38
Slide 20: Magnitude of Reduction and Normalization of Liver Fat Comparable to Phase 2a BALANCED
Magnitude of Reduction and Normalization of Liver Fat Comparable 1 to Phase 2a BALANCED Study Proportion of Patients Achieving LS Mean Relative Percent Change From Baseline Fat Reduction Thresholds at Week 24 in Liver Fat at Week 24 0% Placebo EFX 28mg EFX 50mg Endpoint -10% (N=42) (N=38) (N=35) -6%
Slide 21: Rapid and Sustained Statistically Significant Improvements in Markers of Liver Injury
Rapid and Sustained Statistically Significant Improvements in Markers of Liver Injury ALT AST LS Mean [SE] Change from Baseline (U/L) LS Mean [SE] Change from Baseline (U/L) Baseline: 50-63 U/L Baseline: 42-57 U/L 10 10 0 0 -2 U/L -3 U/L -2% -4% ** *** -10 -10 *** *** *** *** *** *** *** *** *** -21
Slide 22: Statistically Significant Reductions in Non-Invasive Markers Reflect Histological Improvement in Fibrosis
Statistically Significant Reductions in Non-Invasive Markers Reflect Histological Improvement in Fibrosis LS Mean Change From Baseline to Week 24 Pro-C3 (µg/L) ELF Score Liver Stiffness by FibroScan (kPa) 1 0.2 0 +0.1 +0.1 0.1 0 0.0 -1 -0.7 -1 -0.1 -0.2 -2 -2 -0.3 † † -3 - -2.6 2.6 -0.4 -3 -0.5 -4 -
Slide 23: Treatment-Emergent Adverse Events (TEAE)
Treatment-Emergent Adverse Events (TEAE) Placebo EFX 28mg EFX 50mg TEAE Overview (N=43) (N=40) (N=43) TEAE Leading to Death 0 (0%) 0 (0%) 0 (0%) a,b Drug-Related Serious Adverse Event (SAE) 0 (0%) 0 (0%) 1 (2%) c d,e Drug-Related TEAE Leading to Discontinuation 0 (0%) 2 (5%) 2 (5%) Most Frequent (≥1
Slide 24: Clinically Meaningful Improvements in Glycemic Control and Insulin Sensitivity
Clinically Meaningful Improvements Observed in Glycemic Control and Insulin Sensitivity, Particularly in Patients with T2D 2 LS Mean Change From Baseline to Week 24 1 3 HbA1c(%) C-Peptide T2D Subset All T2D Subset All 0.0 0.0 20% 20% +16% 0.0 0.0 15% 15% -0.1 -0.1 +9% 10% 10% -0.2 -0.2 5% 5% 0% 0% -
Slide 25: Substantial Increases Observed in Adiponectin
Substantial Increases Observed in Adiponectin, a Marker of Insulin Sensitizing Action of EFX Adiponectin, LS Mean Change From Baseline at Week 24 (%) 100 *** +91% 90 80 70 60 50 ** +44% 40 30 20 +10% 10 0 Placebo EFX 28mg EFX 50mg N=42 N=36 N=33 ** p<0.01, *** p<0.001, versus placebo (MMRM) Source D
Slide 26: Statistically Significant Improvements Observed in Lipoprotein Profile
Statistically Significant Improvements Observed in Lipoprotein Profile LS Mean Change From Baseline to Week 24 (%) Triglycerides LDL Cholesterol Non-HDL Cholesterol HDL Cholesterol +9% 10% 10% 10% 35% +9% +8% *** *** + +30 30% % 8% 30% 6% 5% *** *** + +24 24% % 0% 25% 4% 20% 2% 0% -10% 0% 15% -2% -5
Slide 27: Weight Loss Observed for 50mg EFX Dose Group
Weight Loss Observed for 50mg EFX Dose Group Body Weight, LS Mean Change at Week 24 (kg) 2.0 1.0 0.0 -0.2 -1.0 -0.6 -2.0 -3.0 †† †† - -2. 2.9 9 †† †† (-2.6% ) -4.0 -5.0 1 Placebo EFX 28mg EFX 50mg N=42 N=37 N=36 †† p<0.01, versus baseline (MMRM) Source Data: Full Analysis Set, non-missing values onl
Slide 28: Cohort D Study Design
Cohort D Study Design 12 Weeks Primary Endpoint • Safety & Tolerability Placebo (N=10) Secondary Endpoints Key Inclusion Criteria • MRI-PDFF • Biopsy-confirmed NASH (F1-F3) • Fibrosis Markers a • Stable Dose of GLP-1 • ALT/AST • HbA1c • C-peptide EFX 50mg (N=21) • Lipoproteins • Weight Change Liver
Slide 29: Patient Disposition & Key Analysis Sets
Week 12 Patient Disposition & Key Analysis Sets Randomized (N=32) Randomized Not Dosed Placebo (N=1) Full Analysis Set – All patients who were randomized and received at Dosed (N=31) least one dose of study drug Safety Set - All subjects who received at least one dose of study drug Discontinued Prio
Slide 30: Baseline Demographics
Baseline Demographics Placebo EFX 50mg Parameter (Mean) (N=10) (N=21) Age (Years) 55 59 Sex (% Female) 90 43 Weight (kg) 96 101 Fibrosis Stage (% F1 / F2 / F3) 40 / 10 / 50 38 / 33 / 29 1 Hepatic Fat Fraction by MRI-PDFF (%) 15 11 2 Pro-C3 (μg/L) 34 33 Enhanced Liver Fibrosis (ELF) Score 9.6 9.2 3 L
Slide 31: Concomitant Diabetic Medications at Baseline
Concomitant Diabetic Medications at Baseline Placebo EFX 50mg GLP-1s (N=10) (N=21) 60% 43% Semaglutide Dulaglutide 30% 52% Liraglutide 10% 5% 1 Tirzepatide 0% 0% Other Diabetic Medications Placebo EFX 50mg Metformin 70% 76% Insulin 30% 48% SGLT-2 20% 33% Sulfonylureas 20% 24% DPP-IV 0% 10% 1 With on
Slide 32: Primary Endpoint: Comparable Safety and Tolerability Across Both Treatment Groups
Primary Endpoint: Comparable Safety and Tolerability Across Both Treatment Groups Treatment-Emergent Adverse Event (TEAE) Placebo EFX 50mg (N=10) (N=21) Overview TEAE Leading to Death 0 (0%) 0 (0%) a Drug-Related Serious Adverse Event (SAE) 0 (0%) 0 (0%) b Drug-Related TEAE Leading to Discontinuatio
Slide 33: Significantly Greater Relative Reductions in Liver Fat for EFX Combined with GLP-1
Significantly Greater Relative Reductions in Liver Fat by MRI-PDFF for EFX Combined with GLP-1 than GLP-1 Alone LS Mean Relative Percent Change From Baseline in Liver Fat at Week 12 0% -10% -10% -20% -30% -40% -50% -60% *** *** -70% -65% Placebo EFX 50mg N=10 N=16 *** 1 p<0.001, versus placebo (ANCO
Slide 34: EFX Liver Fat Reduction in Context: NAFLD & Pre-Cirrhotic NASH
EFX Liver Fat Reduction in Context: NAFLD & Pre-Cirrhotic NASH Akero Akero Akero Madrigal Inventiva Novo Nordisk Novo Nordisk Madrigal 2 Semaglutide EFX Cohort D EFX BALANCED EFX HARMONY Pegozafermin Pemvidutide Liraglutide Tirzepatide Resmetirom Phase 1/2 Phase 2b Phase 2a Phase 2b Phase 2b Phase 1
Slide 35: More Patients Treated with EFX Combined with GLP-1 Met Higher Thresholds of Liver Fat Reduction
More Patients Treated with EFX Combined with GLP-1 Met Higher Thresholds of Liver Fat Reduction and Normalization than GLP-1 Alone Proportion of Patients Achieving Liver Fat Reduction Thresholds at Week 12 ≥ 50% Relative Reduction Normalization of Liver Fat (≤ 5%) ≥ 70% Relative Reduction 100% 100%
Slide 36: Greater Reductions in Markers of Fibrosis for EFX Combined with GLP-1
Greater Reductions in Markers of Fibrosis for EFX Combined with GLP-1 than GLP-1 Alone LS Mean Change From Baseline to Week 12 1 2 Pro-C3 (µg/L) ELF Score Liver Stiffness (kPa) FAST Score 0 0.2 0 0.05 +0.04 +0.1 0.1 0.00 0.0 -1 -0.1 -2 -1.1 -0.05 -0.2 -2 -0.3 -2.7 -0.10 -0.4 -4 -0.5 -3 -0.15 ††† -0.
Slide 37: Greater Reductions in Markers of Liver Injury for EFX Combined with GLP-1
Greater Reductions in Markers of Liver Injury for EFX Combined with GLP-1 than GLP-1 Alone ALT AST LS Mean Change from Baseline (U/L) LS Mean Change from Baseline (U/L) Baseline: 31 U/L (Placebo); 35 U/L (EFX) Baseline: 24 U/L (Placebo); 26 U/L (EFX) 2 2 1 0 +1.5 U/L 0 -2 -1 U/L -1 -4 -2 -3 -6 -4 -8
Slide 38: Clinically Meaningful Improvements in HbA1c after Only 12 Weeks
Clinically Meaningful Improvements in HbA1c after Only 12 Weeks 1 HbA1c HbA1c Normalization LS Mean Change in HbA1c Proportion of Patients with 1 From Baseline to Week 12 Normalized HbA1c at Week 12 30% 0.2 0.1 23% 0.0 20% -0.1 -0.2 10% -0.2 -0.3 -0.4 0% ††† ††† -0.5 -0.5 0% 1 1 Placebo EFX 50mg Pla
Slide 39: EFX Complements GLP-1 by Increasing Sensitivity to Insulin
EFX Complements GLP-1 by Increasing Sensitivity to Insulin LS Mean Change From Baseline to Week 12 C-Peptide Insulin Adiponectin 140% 10% 0% ** +1 +129 29% % 120% 0% 100% -10% -3.5% 80% -10% -13% 60% -20% 40% -20% +16% † 20% -22% -26% -30% -30% 0% 1 Placebo EFX 50mg Placebo EFX 50mg Placebo EFX 50mg
Slide 40: Much Greater Improvements in Lipids for Patients Treated with EFX in Combination with GLP-1
Much Greater Improvements in Lipids for Patients Treated with EFX in Combination with GLP-1 than GLP-1 Alone LS Mean Percent Change From Baseline to Week 12 Triglycerides Non-HDL Cholesterol Apolipoprotein B LDL Cholesterol HDL Cholesterol *** 0% 0% 0% 0% 40% +38% 35% -4.1% -10% -5% -5% -2% -4.5% 30
Slide 41: Weight Loss Maintained for EFX Combined with GLP-1
Weight Loss Maintained for EFX Combined with GLP-1 Body Weight, LS Mean Change at Week 12 (kg) 0.00 -0.25 -0.50 -0.75 -0.8 -1.00 -1.25 -1.2 Placebo EFX 50mg N=10 N=21 ©2023 AKERO THERAPEUTICS. Source Data: Full Analysis Set; Topline preliminary data 41
Slide 42: Cohort D Adds to a Growing Body of Evidence for EFX
Cohort D Adds to a Growing Body of Evidence for EFX’s Potential as a Cornerstone NASH Treatment Key Take-Aways Complementing GLP-1 Potential for EFX on Top of GLP-1 to be More Effective than GLP-1 Alone v EFX and GLP-1 have complementary mechanisms of action. v Addition of EFX to GLP-1 in patients w
Slide 43: Evaluating EFX in Patients with Cirrhosis Due to NASH (F4)
Evaluating EFX in Patients with Cirrhosis Due to NASH (F4) Building on Encouraging 16-Week Data in Patients with F4 Fibrosis a FIBROSIS NASH 58% or in Phase 2a IMPROVEMENT RESOLUTION Achieved a 7 of 12 (58%) patients treated with EFX 50mg in a 16-week expansion cohort (Cohort C) of the Phase 2a BALA
Slide 44: Value of Preventing Progression to & Reversing From Cirrhosis
Value of Preventing Progression to & Reversing From Cirrhosis Survival Free of Liver Transplantation 100% 80% F0 ~50% 60% 5-year mortality 50% F1 without liver transplant 40% F2 for F4 patients F3 20% F4 P<0.001 0% Follow-up (years) Angulo, P et al. (2015) Gastroenterology 149:389-397 ©2023 AKERO TH
Slide 45: Design of Phase 2a Proof-of-Concept Trial for Cirrhotic NASH (F4)
Design of Phase 2a Proof-of-Concept Trial for Cirrhotic NASH (F4) 16 WEEKS Primary Endpoint • Safety & tolerability Placebo (n=10) Key Inclusion Criteria • Compensated cirrhosis (F4), Child-Pugh Class A Key Secondary Endpoints • Histology • Fibrosis markers EFX 50 mg (n=20) • Glycemic control • Lipo
Slide 46: High Rate of Fibrosis Improvement After Only 16 Weeks Among Patients with Cirrhosis
High Rate of Fibrosis Improvement After Only 16 Weeks Among Patients with Cirrhosis (F4 NASH) Fibrosis Improvement ≥1 Stage Without 1,2 Worsening of NASH 40% 33% 30% 20% 4 10% 0% 0% Overall Placebo EFX 50mg n=5 n=12 1 2 No increase in NAS for ballooning, inflammation, or steatosis; Study not powered
Slide 47: EFX Results In Context: Fibrosis Improvement (F4)
* EFX Results In Context: Fibrosis Improvement (F4) Fc-FGF21 ASK-1 Peg-FGF21 GAL-3 FXR FGF19 GLP-1 Efruxifermin Selonsertib Pegbelfermin Belapectin Obeticholic acid Aldafermin Semaglutide 16 Wks (Ph2a) 48 Wks (Ph3) 48 Wks (Ph2b) 52 Wks (Ph2b) 78 Wks (Ph3) 48 Wks (Ph2b) 48 Wks (Ph2b) SC Injection Ora
Slide 48: NASH Resolution Also Observed in Patients with Cirrhosis (F4 NASH)
NASH Resolution Also Observed in Patients with Cirrhosis (F4 NASH) 1,2 NASH Resolution 30% Change in NAS among Subjects Achieving NASH Resolution 25% EFX Subject Baseline NAS Week 16 NAS 20% A 7 1 B 3 1 C 6 1 3 10% Proportion of Subjects with ≥2 Point NAS Reduction Placebo EFX 50mg 0% 0% 1 (20%) 7 (
Slide 49: Improvements in Fibrosis Biomarkers in Patients with Cirrhosis Support Histology Results
Improvements in Fibrosis Biomarkers in Patients with Cirrhosis Support Histology Results (F4 NASH) LS Mean Change From Baseline to Week 16 1 Pro-C3 (µg/L) ELF Score Liver Stiffness (kPa) 0 0 0.4 +0.3 0.3 -1 -2 0.2 -2 -1.9 0.1 -4 -3.4 -3 0.0 -0.1 -4 -6 -0.2 -5 -0.3 -8 -6 †† -5.7 -0.4 ** * -0.4 -9.0 -
Slide 50: Placebo-Corrected Reductions in Cohort C (F4) Fibrosis Markers Consistent with HARMONY
Placebo-Corrected Reductions in Cohort C (F4) Fibrosis Markers Consistent with Magnitude Observed for HARMONY (F2-F3) a b LS Mean Placebo-Corrected Change From Baseline to Week 24 or Week 16 1 Pro-C3 (µg/L) ELF Score Liver Stiffness (kPa) EFX 28mg EFX 50mg EFX 50mg EFX 28mg EFX 50mg EFX 50mg EFX 28m
Slide 51: SYMMETRY Trial Design: Cirrhosis Due to NASH (F4)
SYMMETRY Trial Design: Cirrhosis Due to NASH (F4) Key Inclusion Criteria Key Secondary Efficacy Endpoints Phase 2b Primary Endpoint • F4 NASH • Fibrosis Improvement • NASH Resolution • Glycemic Control (Cirrhosis reversal) • Fibrosis Markers • Weight Change • Lipoproteins • Liver Injury Markers Long
Slide 52: Looking Ahead
ak=ro Looking Ahead
Slide 53: Looking Ahead to Phase 2b SYMMETRY Readout and Initiation of Phase 3 SYNCHRONY Studies
Looking Ahead to Phase 2b SYMMETRY Readout in Patients with Cirrhosis and Initiation of Phase 3 SYNCHRONY Studies Phase 2b Phase 3 F2-F3 F1-F3 F4 F2-F3 F1-F3 Patient Population: Cohort D SYNCHRONY SYNCHRONY Real- HARMONY (Expansion of Histology World SYMMETRY) Enrollment Complete; Primary Endpoint I
Slide 54: Introducing the SYNCHRONY Phase 3 Program
Introducing the SYNCHRONY Phase 3 Program Three Planned Parallel Randomized, Placebo-Controlled Clinical Trials • Biopsy confirmed F2-F3 NASH • Non-invasively diagnosed NASH/NAFLD Design to be finalized following • Primary endpoint: ≥ 1-stage fibrosis • Primary endpoint: safety & tolerability SYMMET
Slide 55: Supplying API and Drug Product/Device for Phase 3
Supplying API and Drug Product/Device for Phase 3 Drug Substance (API) Drug Product/Device Combination Commercial scale Commercially precedented Released for Phase 3 Released for Phase 3 Comparability demonstrated 1 mL SC weekly injection Self-administered, stable at 2-8ºC ©2023 AKERO THERAPEUTICS.
Slide 56: Backup Slides
ak=ro Backup Slides
Slide 57: EFX's Four Attachment Points to Cellular Surface May Contribute to Stronger Receptor Binding
EFX’s Four Attachment Points to Cellular Surface May Contribute to Stronger Receptor Binding and Enhanced Efficacy EFX Single-chain FGF21 Dimer structure may enable cooperative binding Two independent binding events preclude and enhance avidity effects cooperative binding or avidity effects ©2023 AK
Slide 58: Supportive Evidence for EFX's Cooperative Binding to Cell Surface
Supportive Evidence for EFX’s Cooperative Binding to Cell Surface EFX (bivalent Fc-RGE) Monovalent RGE Monovalent Fc-RGE Monovalent 173-PEG20 association dissociation association dissociation association dissociation association dissociation No chase (labeled ligand removed) Single-chain FGF21 has s
Slide 59: Single FGF21 chain analogs are less potent than EFX
Single FGF21 chain analogs fused to “half-life extenders” are 15- to 30- Fold Less Potent than EFX with two FGF21 chains’ or “unmodified FGF21” Bivalent Monovalent Monovalent Monovalent Fc-RGE RGE Fc-RGE 173-PEG20 (EFX) 20 kDa PEG Half-life extension Fc-fusion minimal Fc-fusion at residue 173 N-term
Slide 60: Potential for Translation from Phase 2 to Phase 3: Fibrosis Improvement
Potential for Translation from Phase 2 to Phase 3: Fibrosis Improvement Akero Madrigal Madrigal Efruxifermin Resmetirom Resmetirom Phase 2b (F2-F3) Phase 2 (F1-F3) Phase 3 (F1-F3) 66% F3 20% F3 62% F3 1 2 3 24 Wks / Completers 36 Wks / Completers 52 Wks / ITT Consensus Readers Single Reader Two Read
Slide 61: Potential for Translation from Phase 2 to Phase 3: NASH Resolution
Potential for Translation from Phase 2 to Phase 3: NASH Resolution Akero Madrigal Madrigal Efruxifermin Resmetirom Resmetirom Phase 2b (F2-F3) Phase 2 (F1-F3) Phase 3 (F1-F3) 66% F3 20% F3 62% F3 1 2 3 24 Wks / Completers 36 Wks / Completers 52 Wks / ITT Consensus Readers Single Reader Two Readers (
Slide 62: From BALANCED to HARMONY Endpoints
From BALANCED to HARMONY Endpoints Placebo EFX 28mg EFX 50mg % Responders, Histology and Liver Fat Normalization HARMONY BALANCED HARMONY BALANCED HARMONY Fibrosis improvement ≥ 1 stage and no worsening of NASH 20 46 39 62 41 NASH resolution and no worsening of fibrosis 15 46 47 54 76 Fibrosis impro
Slide 63: High Level of Consistency Across Four Clinical Studies of EFX
High Level of Consistency Across Four Clinical Studies of EFX EFX 50mg EFX 50mg EFX 50mg EFX 50mg 1 2 3 4 BALANCED Cohort C HARMONY Cohort D Endpoints Non-Invasive Tests F1-F3 F4 F2-F3 F1-F3 16 Weeks 16 Weeks 24 Weeks 12 Weeks Pro-C3 (μg/L) -4.7 -9.5 -5.2 -5.2 ELF Score -0.7 -0.4 -0.7 -0.6 LS Mean L
Slide 64: Akero Therapeutics, South San Francisco, CA
AKERO THERAPEUTICS 601 Gateway Boulevard NASDAQ: AKRO Suite 350 South San Francisco, CA 94080
Akero Therapeutics — Investor Presentation (June 2023) on 6ix